ArticleMarine drugs2019
Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Organoid Models of Colorectal Pathology: Do They Hold the Key to Personalized Medicine? A Systematic Review.Diseases of the colon and rectum · 2020Pooled it
- Chemical richness and diversity of uncultivated 'Entotheonella' symbionts in marine sponges.Nature chemical biology · 2026Article
- Calcitriol Modulates Age-dependent Drug Response in Paired Patient-derived Normal and Tumor Colorectal Organoids.International journal of biological sciences · 2026Article
- Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab.Journal of pharmaceutical analysis · 2025Article
- A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors.Investigational new drugs · 2024Article
- Translational Utility of Organoid Models for Biomedical Research on Gastrointestinal Diseases.Stem cell reviews and reports · 2024Review
- Application of organoids in otolaryngology: head and neck surgery.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Review
- Cancer organoids: A platform in basic and translational research.Genes & diseases · 2024Review
- Construction of tumor organoids and their application to cancer research and therapy.Theranostics · 2024Review
- An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2023Article
- Tumor organoid model of colorectal cancer (Review).Oncology letters · 2023Review
- Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment.Biomedicines · 2023Review
- Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report.Journal of gastrointestinal oncology · 2023Article
- The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer.Cancers · 2023Review
- Effect of the Marine Polyketide Plocabulin on Tumor Progression.Marine drugs · 2022Review
- Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASCommunications biology · 2022Article
- Q-TOF LC-MS compounds evaluation of propolis extract derived from Malaysian stingless bees,Saudi journal of biological sciences · 2022Article
- Natural Marine Products: Anti-Colorectal Cancer In Vitro and In Vivo.Marine drugs · 2022Review
- Modeling colorectal cancer: A bio-resource of 50 patient-derived organoid lines.Journal of gastroenterology and hepatology · 2022Article
- Establishment of a patient-derived organoid model and living biobank for nasopharyngeal carcinoma.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Plocabulin is a novel microtubule-disrupting antitumor agent of marine origin that is currently undergoing phase II clinical trials. Plocabulin has potent antiproliferative and antiangiogenic actions in carcinoma cell lines and has antitumor activity in xenografted mice. Here, we used three-dimensional (3D) tumor organoids derived from three colorectal cancer (CRC) patients to study the effect of plocabulin in a personalized assay system that ensures dose dependence and high reproducibility. The cytotoxicity of plocabulin was an order of magnitude higher than that of the active irinotecan derivative SN38 (7-ethyl-10-hydroxy-camptothecin) in tumor organoids at different passages. Moreover, plocabulin maintained its strong cytotoxic activity in wash-out experiments, in which a short pulse treatment of tumor organoids was as efficient as continuous treatment. Our data show that plocabulin has a very potent cytotoxic action in CRC patient-derived tumor organoids, supporting ongoing clinical trials with plocabulin and the use of organoid assays to provide personalized validation of antitumor drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.